Mahoney: Too much CEO turnover at Boston Scientific

Tue, 01/08/2013 - 3:02pm
Mass Device

New Boston Scientific CEO Michael Mahoney is in it for the long haul, he tells investors at the J.P. Morgan Healthcare conference.

Michael Mahoney headshot

There's been too much turnover in the corner office at Boston Scientific (NYSE:BSX), and Michael Mahoney aims to change that, he told an audience at the J.P. Morgan Healthcare Conference in San Francisco today.

"I'm really making a long-term commitment to the company," Mahoney said today. "I absolutely love it, I'm enjoying what I'm doing."

Mahoney officially took over the corner office in November 2011, marking the end of a year-long "transition period" for the new CEO. He had spent just over a year at Boston Scientific as president, after being recruited from rival device maker Johnson & Johnson's (NYSE:JNJ) diagnostics and devices group.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.